CAN-FITE BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.7 ILa | -3.57% |
|
-3.57% | +3.85% |
| May. 12 | Transcript : Can-Fite BioPharma Ltd. - Special Call | |
| May. 09 | Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study | CI |
| Sales 2024 * | 900K 334M | Sales 2025 * | 900K 334M | Capitalization | 10.91M 4.04B |
|---|---|---|---|---|---|
| Net income 2024 * | -7M -2.6B | Net income 2025 * | -8M -2.97B | EV / Sales 2024 * | 12.1 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 12.1 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Can-Fite BioPharma Ltd.
More press releases
| 1 day | -3.57% | ||
| 1 week | -3.57% | ||
| 1 month | +3.85% | ||
| 3 months | +3.85% | ||
| 6 months | -3.57% | ||
| Current year | +3.85% |
1 week
2.70
2.90
1 month
2.603.00
Current year
2.503.00
1 year
2.504.10
3 years
2.1031.10
5 years
2.1052.80
10 years
2.101 163.00
| Managers | Title | Age | Since |
|---|---|---|---|
Motti Farbstein
CEO | Chief Executive Officer | 59 | 03-07-31 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Abraham Sartani
BRD | Director/Board Member | 76 | 00-12-31 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-30 | 2.7 | -3.57% | 7,657,102 |
| 24-05-29 | 2.8 | -.--% | 10,226,920 |
| 24-05-28 | 2.8 | -.--% | 1,751,177 |
| 24-05-27 | 2.8 | -.--% | 1,206,422 |
| 24-05-26 | 2.8 | -.--% | 1,703,320 |
Delayed Quote TEL AVIV STOCK EXCHANGE, May 30, 2024 at 10:24 am EDT
More quotes
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Sector
Pharmaceuticals
Calendar
2024-06-02
- Bio International Convention
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.027
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.85% | 10.88M | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -22.14% | 14.25B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B |
- Stock Market
- Equities
- CANF Stock
